Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 27,297 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 27,297 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $0.92, for a total transaction of $25,113.24. Following the completion of the transaction, the director owned 3,287,551 shares of the company’s stock, valued at approximately $3,024,546.92. This trade represents a 0.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Monday, November 24th, Luke Evnin sold 56,992 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $55,852.16.
• On Friday, November 21st, Luke Evnin sold 41,287 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.83, for a total value of $34,268.21.
• On Thursday, November 20th, Luke Evnin sold 26,411 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total value of $23,505.79.
• On Wednesday, November 19th, Luke Evnin sold 42,566 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $40,012.04.
• On Tuesday, November 18th, Luke Evnin sold 33,776 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total value of $31,411.68.
• On Monday, November 17th, Luke Evnin sold 36,621 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total value of $34,789.95.
• On Friday, November 14th, Luke Evnin sold 39,560 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total value of $36,790.80.
• On Thursday, November 13th, Luke Evnin sold 58,372 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $57,204.56.
• On Wednesday, November 12th, Luke Evnin sold 26,101 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total transaction of $28,450.09.
• On Tuesday, November 11th, Luke Evnin sold 35,818 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $40,832.52.

Werewolf Therapeutics Price Performance

HOWL traded down $0.07 during midday trading on Tuesday, hitting $0.91. 461,162 shares of the company traded hands, compared to its average volume of 505,004. The business has a 50 day simple moving average of $1.52 and a two-hundred day simple moving average of $1.34. Werewolf Therapeutics, Inc. has a 52-week low of $0.60 and a 52-week high of $2.38. The company has a market capitalization of $44.19 million, a price-to-earnings ratio of -0.56 and a beta of 0.73. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HOWL has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. JMP Securities dropped their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Citigroup restated a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Zacks Research cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday. Finally, Bank of America reduced their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Quadrature Capital Ltd purchased a new stake in shares of Werewolf Therapeutics in the second quarter valued at about $28,000. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics in the 2nd quarter valued at about $48,000. Nuveen LLC purchased a new stake in shares of Werewolf Therapeutics in the 1st quarter valued at approximately $71,000. AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics in the 1st quarter valued at approximately $79,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth approximately $92,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.